<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055194</url>
  </required_header>
  <id_info>
    <org_study_id>AntenatalTRX-PP</org_study_id>
    <nct_id>NCT04055194</nct_id>
  </id_info>
  <brief_title>Antenatal Tranexamic Acid in Women With Symptomatic Placenta Previa</brief_title>
  <official_title>Efficacy of Antenatal Tranexamic Acid in Pregnant Women With Symptomatic Placenta Previa in Decreasing Antepartum Hemorrhage - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      200 pregnant women with symptomatic placenta previa with previous bleeding attacks attending
      Ain Shams University maternity hospital will be recruited and randomized to receive either
      tranexamic acid tablets (500mg four times daily) or placebo. Amount of bleeding during
      antepartum bleeding attacks will be estimated (by hemoglobin change from baseline at
      admission till delivery).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pregnant women with symptomatic placenta previa with previous bleeding attacks will be recruited and randomized to receive either tranexamic acid tablets (500mg four times daily) or placebo till delivery. Amount of bleeding during antepartum bleeding attacks will be estimated (by hemoglobin change from baseline at admission till delivery).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Visually-identical drug and placebo tablets will be assigned to each participant using SNOSE congaing assignment code.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of bleeding during antepartum bleeding attacks</measure>
    <time_frame>9 weeks GA</time_frame>
    <description>Amount of bleeding during antepartum bleeding attacks will be estimated by hemoglobin change from baseline at admission till delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of women requiring antepartum blood transfusion</measure>
    <time_frame>9 weeks GA</time_frame>
    <description>Number of women requiring antepartum blood transfusion for resuscitation after severe antepartum hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of PRBCs units required during antepartum blood transfusion</measure>
    <time_frame>9 weeks GA</time_frame>
    <description>Number of PRBCs required during antepartum blood transfusion for resuscitation after severe antepartum hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pregnant women experiencing severe antepartum hemorrhage necessitating urgent delivery</measure>
    <time_frame>9 weeks GA</time_frame>
    <description>Number of pregnant women experiencing severe antepartum hemorrhage necessitating urgent delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>9 weeks GA</time_frame>
    <description>Gestational age in weeks at the time of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care unit (NICU) admission</measure>
    <time_frame>9 weeks</time_frame>
    <description>Number of neonates requiring NICU admission.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Placenta Previa</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid tablets</intervention_name>
    <description>Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.</description>
    <arm_group_label>Tranexamic acid group</arm_group_label>
    <other_name>Kapron(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age 28 weeks of gestation.

          -  Definite and reliable diagnosis of placenta previa (defined as presence of a placenta
             within 2 cm of the internal os), using transvaginal ultrasound scan.

          -  Haemodynamically stable pregnant women.

          -  Maternal age:20-40years old.

          -  Pregnant women with placenta previa, and had previous bleeding attacks or admitted
             with antepartum haemorrhage.

        Exclusion Criteria:

          -  Multiple pregnancy.

          -  Women with bleeding tendency due to any medical disorder (ITP, thrombocytopenia,
             coagulopathies),or on anticoagulants .

          -  Severe antepartum hemorrhage and/or hemodynamic instability that necessitates urgent
             intervention and delivery.

          -  Women have hypersensitivity or any contraindication to use of tranexamic acid.

          -  Pregnant women with placenta previa with doppler showing morbidly adherent placenta.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amal Ramadan, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>A Ramadan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amal Ramadan, MBBCh</last_name>
    <phone>+201098093525</phone>
    <email>dr.amalramadan11@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain SHams Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Abbaseya</state>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amal Ramadan, MBBCh</last_name>
      <phone>201098093525</phone>
      <email>dr.amalramadan11@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 10, 2019</study_first_submitted>
  <study_first_submitted_qc>August 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>August 10, 2019</last_update_submitted>
  <last_update_submitted_qc>August 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Amal Ramadan</investigator_full_name>
    <investigator_title>Clinical fellow of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Previa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

